CLINICAL CHARACTERISTICS AND OUTCOMES OF HOSPITALIZED PATIENTS WITH HEART FAILURE AND SARCOIDOSIS: ANALYSIS OF THE NATIONWIDE READMISSIONS DATABASE 2010-2019

Author:

Ahmed RaheelORCID,Sawatari HiroyukiORCID,Amanullah Khadija,Okafor Joseph,Irfan Wafa Syed Emir,Deshpande Saurabh,Ramphul Kamleshun,Ali Isma,Khanji MohammedORCID,Wells Athol,Ezzeddin Omar,Kouranos VasilisORCID,Sharma Rakesh,Somers Virend K.ORCID,Mohammed Selma F.ORCID,Chahal C. Anwar A.ORCID

Abstract

ABSTRACTBACKGROUNDSarcoidosis is a multi-systemic granulomatous inflammatory disorder. In the setting of cardiac involvement, clinical manifestations include ventricular arrhythmias, high-grade atrioventricular block (AVB) and heart failure (HF). The impact of HF in patients with sarcoidosis has not been established from real-world data.METHODSPatients admitted with sarcoidosis from 2010-2019 were identified from the Nationwide Readmissions Database. Those with ischemic heart disease were excluded. Sarcoidosis patients without HF were propensity matched for age, gender and Charlson comorbidity index and compared to patients with HF. Clinical characteristics, length of stay (LOS), adjusted healthcare-associated costs (HAC), 90-day readmission and 90-day mortality was observed.RESULTSDuring the 10-year study period, 97,961 patients (median age 63 [54-71] years, 37.9% male) with a diagnosis of sarcoidosis were hospitalized (35.9% with HF and 64.1% without HF). On index admission, HF patients had a higher prevalence of AVB (3.3% vs 1.4%, p<0.0001), ventricular tachycardia (6.5% vs 1.3%, p<0.0001), ventricular fibrillation (0.4% vs 0.1%, p<0.0001) and atrial fibrillation (22.1% vs 7.5%, p<0.0001). The median LOS (4 [3-7] vs. 4[2-6] days, p<0.0001) was similar but median HAC (US$ 9,954.5 [5,934.7-18,128.8] vs. 8,828.3 [5,303.1-15,384.9], p<0.0001) during the index admission were higher in HF patients.The LOS and HAC were greater in HF patients on 90-day readmission. HF patients were significantly more likely to be re-admitted within 90 days [adjusted all-cause readmissions (HR [95% CI: 1.28 [1.25 – 1.31], p<0.0001), atrial fibrillation (HR 1.35 [1.05-1.75], p=0.02), acute HF (HR 10.77 [9.45 – 12.16], p<0.0001) and ventricular tachycardia/ventricular fibrillation (HR 2.55 [1.69 – 3.85], p<0.0001)]. Adjusted inpatient mortality at readmission was also higher in HF patients (5.1% vs. 3.8%, p<0.0001).CONCLUSIONThe presence of HF in hospitalized sarcoidosis patients is associated with an increased prevalence of conduction disorders, ventricular arrhythmias and atrial fibrillation. HF patients had greater costs, readmissions and mortality at 90-days.What is known?1)Cardiac involvement in sarcoidosis is associated with ventricular arrhythmias, high-grade atrioventricular block and heart failure2)Retrospective small, single-center studies have reported relatively poor long-term survival outcomes for symptomatic cardiac sarcoidosis patients with reduced left ventricular ejection fractionWhat the study adds?1)Using a large real-world database, this study has demonstrated that heart failure in hospitalized sarcoidosis patients is associated with increased prevalence of arrythmia, conduction disorders, cardiac implanted electronic devices, catheter ablations and cardiac transplantation.2)Heart failure in hospitalized sarcoidosis patients leads to a significantly higher length of stay, healthcare-adjusted costs, 90-days readmissions and mortality following readmission.

Publisher

Cold Spring Harbor Laboratory

Reference39 articles.

1. Sarcoidosis: A nationwide registry-based study of incidence, prevalence and diagnostic work-up;Respir Med,2021

2. Epidemiology of sarcoidosis: current findings and future directions;Ther Adv Chronic Dis,2018

3. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders;Sarcoidosis Vasc Diffuse Lung Dis,1999

4. Causes of death in patients with sarcoidosis. A morphologic study of 38 autopsies with clinicopathologic correlations;Arch Pathol Lab Med.,1995

5. New Guidelines for Diagnosis of Cardiac Sarcoidosis in Japan;Annals of Nuclear Cardiology,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3